Management of hypertension: Evidence from the Blood Pressure Lowering Treatment Trialists' Collaboration and from major clinical trials

Polskie Archiwum Medycyny Wewnetrznej

Volumn 119, Issue 6, 2009, Pages 373-380

  Chalmers, John ^a   Arima, Hisatomi ^b  

^a ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Absolute risk; Blood pressure lowering; Combination therapy; Management of hypertension; Total cardiovascular risk

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT;

ASIAN; BLOOD PRESSURE; CAUCASIAN; DRUG EFFICACY; DRUG TOLERANCE; HUMAN; HYPERTENSION; REVIEW; SYSTOLIC BLOOD PRESSURE;

EID: 67650465955     PISSN: 00323772     EISSN: None     Source Type: Journal    
DOI: 10.20452/pamw.713     Document Type: Review

References (36)

1. Mancia G, De Backer G, Dominiczak A, et al. 2007 guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2007; 25: 1105-1187. (Pubitemid 46924065)
2. Chobanian AV, Bakris GL, Black HR, et al and the National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003; 42: 1206-1252.
3. World Health Organization, International Society of Hypertension Writing Group. 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens. 2003; 21: 1983-1992.
4. World Health Organization. World health report 2002: reducing risk, promoting healthy life. World Health Organization 2002.
5. MacMahon S, Peto R, Cutler J, et al. Blood pressure, stroke, and coronary heart disease. Part 1, prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet. 1990; 335: 765-774.
6. Rodgers A, Ezzati M, Vander Hoom S, et al. Distribution of major health risks: findings from the Global Burden of Disease study. PLoS Med. 2004; 1: e27. (Pubitemid 40412699)
7. Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002; 360: 1903-1913. (Pubitemid 35472129)
8. Asia Pacific Cohort Studies Collaboration. Blood pressure and cardiovascular diseases in the Asia-Pacific region. J Hypertens. 2003; 21: 707-716. (Pubitemid 36549665)
9. Chalmers J. "Treating hypertension" or "lowering blood pressure"? Extending the concept. Blood Press. 2002; 11: 68-70.
10. HOPE (Heart Outcomes Prevention Evaluation) Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000; 342: 145-153. (Pubitemid 30051645)
11. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood pressure lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet. 2001; 358: 1033-1041. (Pubitemid 32925123)
12. ADVANCE Collaborative Group. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet. 2007; 370: 829-840. (Pubitemid 47362321)
13. Mendis S, Lindholm LH, Mancia G, et al. World Health Organization (WHO) and International Society of Hypertension (ISH) risk prediction charts: assessment of cardiovascular risk for prevention and control of cardiovascular disease in low and middle-income countries. J Hypertens. 2007; 25: 1578-1582. (Pubitemid 47056562)
14. World Health Organization. Preventing chronic disease: guidelines for assessment and management of cardiovasuclar risk. World Health Organization 2007.
15. Mancia G, Ambrosioni E, Rosei EA, et al on behalf of the ForLife study group. Blood pressure control and risk of stroke in untreated and treated hypertensive patients screened from clinical practice: results of the ForLife study. J Hypertens. 2005; 23: 1575-1581. (Pubitemid 41104830)
16. EUROASPIRE I and II Group. Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries. Lancet. 2001; 357: 996-1001.
17. Marques-Vidal P, Tuomilehto J. Hypertension awareness, treatment and control in the community: is the 'rule of halves' still valid? J Hum Hypertens. 1997; 11: 213-220.
18. National Institute for Health and Clinical Excellence. Hypertension: management of hypertension in adults in primary care (partial update of NICE clinical guideline 18). NICE clinical guideline 34. National Institute for Health and Clinical Excelence 2006.
19. Khan NA, Hemmelgam B, Herman RJ, et al for the Canadian Hypertension Education Program. The 2008 Canadian Hypertension Education Program recommendations for the management of hypertension: part 2 - therapy. Can J Cardiol. 2008; 24: 465-475.
20. National Heart Foundation of Australia. Guide to management of hypertension 2008: assessing and managing raised blood pressure in adults. National Heart Foundation of Australia 2008.
21. Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of ACE inhibitors, calcium antagonists and other blood pressure lowering drugs: results of prospectively designed overviews of randomised trials. Lancet. 2000; 355: 1955-1964.
22. Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet. 2003; 362: 1527-1535. (Pubitemid 37410190)
23. Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials. Arch Intern Med. 2005; 165: 1410-1419. (Pubitemid 40973424)
24. Blood Pressure Lowering Treatment Trialists' Collaboration. Blood pressure-dependent and independent effects of agents that inhibit the renin-angiotensin system. J Hypertens. 2007; 25: 951-958. (Pubitemid 46573113)
25. Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials. BMJ. 2008; 336: 1121-1123. (Pubitemid 351731743)
26. Blood pressure Lowering Treatment Trialists' Collaboration. Do men and women respond differently to blood pressure-lowering treatment? Results of prospectively designed overviews of randomized trials. Eur Heart J. 2008; 29: 2669-2680.
27. Dahlöf B, Sever PS, Poulter NR, et al for the ASCOT investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet. 2005; 366: 895-906.
28. Lindholm LH, Carlberg B, Samuelsson O. Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet. 2005; 366: 1545-1553. (Pubitemid 41540112)
29. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic. JAMA. 2002; 288: 2981-2997.
30. Jamerson K, Weber MA, Bakris GL, et al for the ACCOMPLISH trial investigators. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 2008; 359: 2417-2428.
31. The ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008; 358: 1547-1559.
32. The Telmisartan Randomised Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (TRANSCEND) Investigators. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet. 2008; 372: 1174-1183.
33. Yusuf S, Diener HC, Sacco RL, et al for the PRoFESS study group. Telmisartan to prevent recurrent stroke and cardiovascular events. N Engl J Med. 2008; 359: 1225-1237.
34. Chalmers J. The importance of drug combinations for effective control of hypertension. Clin Exp Hypertens. 1999; 21: 875-884. (Pubitemid 29325485)
35. Hallin L, Andren L, Hansson L. Controlled trial of nifedipine and bendroflumethiazide in hypertension. J Cardiovasc Pharmacol. 1983; 5: 1083-1085. (Pubitemid 14234358)
36. Gaede P, Lund-Andersen H, Parving HH, et al. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008; 358: 580-591. (Pubitemid 351214285)